Details for: CYP2U1 AS1

Gene ID: 101929595

Gene Type:  ncRNA (Non-coding RNA)  - A functional RNA molecule that is transcribed from DNA but not translated into a protein. Includes classes like miRNA and lncRNA.

Symbol: CYP2U1 AS1

Ensembl ID: ENSG00000245293

Description: CYP2U1 and SGMS2 antisense RNA 1

Cell Significance Landscape

Significant Cells

Cell Significance Index (CSI) scores for the chosen context(s)

  • melanocyte CL0000148
    CSI 5.09
    rCSI 3.77%
    PRS 97.42
  • pulmonary alveolar type 2 cell CL0002063
    CSI 4.93
    rCSI 7.65%
    PRS 98.34
  • conjunctival epithelial cell CL1000432
    CSI 4.85
    rCSI 7.41%
    PRS 97.66
  • adipocyte CL0000136
    CSI 4.04
    rCSI 5.19%
    PRS 95.69
  • pvalb GABAergic cortical interneuron CL4023018
    CSI 3.93
    rCSI 4.89%
    PRS 94.21
  • brush cell of tracheobronchial tree CL0002075
    CSI 3.73
    rCSI 11.06%
    PRS 99.43
  • alveolar macrophage CL0000583
    CSI 3.51
    rCSI 5.79%
    PRS 98.61
  • lung ciliated cell CL1000271
    CSI 2.98
    rCSI 3.44%
    PRS 96.51
  • cardiac muscle cell CL0000746
    CSI 2.86
    rCSI 4.1%
    PRS 95.18
  • mesothelial cell CL0000077
    CSI 2.73
    rCSI 10.69%
    PRS 93.54
  • sst GABAergic cortical interneuron CL4023017
    CSI 2.45
    rCSI 3.16%
    PRS 95.58
  • L4 intratelencephalic projecting glutamatergic neuron CL4030063
    CSI 2.41
    rCSI 5.76%
    PRS 93.99
  • BEST4+ enteroycte CL4030026
    CSI 2.25
    rCSI 2.8%
    PRS 97.85
  • basal cell of epidermis CL0002187
    CSI 2.24
    rCSI 3.97%
    PRS 82.79
  • regular atrial cardiac myocyte CL0002129
    CSI 1.62
    rCSI 5.23%
    PRS 96.52
  • retinal ganglion cell CL0000740
    CSI 1.25
    rCSI 2.77%
    PRS 94.84
  • L5 extratelencephalic projecting glutamatergic cortical neuron CL4023041
    CSI 1.13
    rCSI 4.05%
    PRS 94.07
  • regular ventricular cardiac myocyte CL0002131
    CSI 1.02
    rCSI 6.35%
    PRS 95.77
  • indirect pathway medium spiny neuron CL4023029
    CSI 0.99
    rCSI 23.83%
    PRS 92.63
  • pulmonary alveolar type 1 cell CL0002062
    CSI 0.78
    rCSI 4.47%
    PRS 97.34
  • ON midget ganglion cell CL4033046
    CSI 0.44
    rCSI 9.01%
    PRS 94.42
  • OFF midget ganglion cell CL4033047
    CSI 0.35
    rCSI 7.22%
    PRS 94.51

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration

Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.

Comma-separated if multiple.
Comma-separated if multiple.
Legend:
  • Query Gene
  • Node Color (Target Cell CSI, relative to current network):
    • Very High
    • High
    • Medium
    • Low
    • Very Low
    • CSI N/A
  • Node Size: Proportional to Target Cell CSI magnitude
  • STRING PPI Edge
  • Shared Pathway Edge (ONTOLOGY)

Loading network (please wait)...

Other Information

This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.

## Summary [CYP2U1 AS1](/details-gene/101929595) is a non-coding antisense RNA located on chromosome 4q25. Its genomic position suggests it regulates the expression of the neighboring genes *CYP2U1* and *SGMS2*, which are involved in lipid metabolism. Expression data indicates that [CYP2U1 AS1](/details-gene/101929595) has a broad but distinct cellular footprint. **Overall**, it shows high significance in a diverse array of cell types, including [melanocytes](/details-cell/CL0000148), various lung epithelial and immune cells such as [pulmonary alveolar type 2 cells](/details-cell/CL0002063), and specialized cells like [adipocytes](/details-cell/CL0000136), suggesting it may play a fundamental regulatory role across multiple tissues. ## Cellular Roles and Expression Landscape The expression profile of [CYP2U1 AS1](/details-gene/101929595) highlights its significance in several distinct biological systems, pointing towards a multifaceted regulatory function rather than a single lineage-specific role. **Overall**, the gene is a prominent feature in multiple epithelial and barrier tissues. It is most significant in [melanocytes](/details-cell/CL0000148) (CSI: 5.09) and shows high significance in [conjunctival epithelial cells](/details-cell/CL1000432) (CSI: 4.85) and [basal cells of the epidermis](/details-cell/CL0002187) (CSI: 2.24). This pattern suggests a potential role in pigmentation, ocular surface maintenance, or skin homeostasis. A second major site of significance is the respiratory system. [CYP2U1 AS1](/details-gene/101929595) is highly significant in [pulmonary alveolar type 2 cells](/details-cell/CL0002063) (CSI: 4.93), [brush cells of the tracheobronchial tree](/details-cell/CL0002075) (CSI: 3.73), [alveolar macrophages](/details-cell/CL0000583) (CSI: 3.51), and [lung ciliated cells](/details-cell/CL1000271) (CSI: 2.98). This strong presence across both epithelial and resident immune cells of the lung points to a potential involvement in processes like surfactant metabolism, airway defense, or inflammatory signaling. The gene also demonstrates relevance in metabolically active cells, with a high CSI in [adipocytes](/details-cell/CL0000136) (CSI: 4.04), and in electrically active tissues, including various cortical interneurons such as [pvalb GABAergic cortical interneurons](/details-cell/CL4023018) (CSI: 3.93) and [cardiac muscle cells](/details-cell/CL0000746) (CSI: 2.86). This wide-ranging expression profile suggests that [CYP2U1 AS1](/details-gene/101929595) may function as a context-dependent regulator of its target genes across diverse physiological systems. ## Pathways and Molecular Function Functional annotation data is not available for [CYP2U1 AS1](/details-gene/101929595). However, as an antisense non-coding RNA, its primary mechanism is likely the regulation of its sense-strand counterparts, *CYP2U1* and *SGMS2*. *CYP2U1* is a member of the cytochrome P450 family involved in fatty acid and lipid metabolism. *SGMS2* (Sphingomyelin Synthase 2) is a key enzyme in sphingolipid biosynthesis. Therefore, [CYP2U1 AS1](/details-gene/101929595) is hypothesized to be a modulator of lipid and sphingolipid metabolic pathways. This putative function is consistent with its high significance in [adipocytes](/details-cell/CL0000136) and [pulmonary alveolar type 2 cells](/details-cell/CL0002063), both of which are heavily involved in lipid processing. ## Research Directions The diverse expression pattern of [CYP2U1 AS1](/details-gene/101929595) opens up several avenues for future investigation into its role in health and disease. Based on its expression profile and presumed function as an antisense regulator, several testable hypotheses can be proposed: 1. [CYP2U1 AS1](/details-gene/101929595) acts as a negative regulator of *CYP2U1* expression in [adipocytes](/details-cell/CL0000136). Its upregulation may contribute to altered lipid metabolism by suppressing fatty acid hydroxylation, potentially impacting conditions like obesity or metabolic syndrome. 2. In the lung, [CYP2U1 AS1](/details-gene/101929595) coordinates lipid metabolism in [pulmonary alveolar type 2 cells](/details-cell/CL0002063) (which produce lipid-rich surfactant) and inflammatory responses in [alveolar macrophages](/details-cell/CL0000583). Dysregulation of this lncRNA could therefore be a contributing factor in respiratory diseases characterized by surfactant dysfunction or chronic inflammation, such as acute respiratory distress syndrome (ARDS) or idiopathic pulmonary fibrosis. 3. The high significance of [CYP2U1 AS1](/details-gene/101929595) in multiple neuronal subtypes suggests a role in regulating brain lipid metabolism, which is critical for neuronal membrane integrity and function. Its dysregulation could be explored in the context of neurodegenerative diseases associated with lipid pathway defects. A key experiment to test the first hypothesis would involve targeted knockdown of [CYP2U1 AS1](/details-gene/101929595) in a human pre-adipocyte cell line differentiated into mature [adipocytes](/details-cell/CL0000136). Using antisense oligonucleotides (ASOs), one could measure the resulting changes in the mRNA and protein levels of *CYP2U1* and *SGMS2* via qRT-PCR and western blot. Subsequent functional assays, such as lipid droplet quantification by Oil Red O staining and analysis of cellular lipid profiles using mass spectrometry, would reveal its direct impact on adipocyte lipid metabolism. Given its nature as a non-coding RNA, [CYP2U1 AS1](/details-gene/101929595) is a candidate for therapeutic intervention using RNA-targeted modalities like ASOs or siRNAs. If its overexpression is linked to pathological lipid accumulation in metabolic diseases, a strategy of therapeutic inhibition could be pursued. Conversely, if its expression is protective, activation strategies might be considered. Its broad expression across multiple healthy tissues would require careful consideration of cell-type specific delivery to minimize off-target effects.